{
  "id": 5564584,
  "title": "Aspen Pharmacare sees weight-loss drugs driving earnings",
  "url": "https://urgent.news/2026/09/04/aspen-pharmacare-sees-weight-loss-drugs-driving-earnings",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T13:08:59.000Z",
  "source": {
    "name": "Semafor",
    "slug": "semafor",
    "url": "https://www.semafor.com/article/09/04/2026/aspen-pharmacare-says-weight-loss-drugs-to-drive-profits"
  },
  "original_language": "en",
  "account": null,
  "summary": "Aspen Pharmacare, a South African drugmaker, anticipates a 17% increase in earnings next year, driven by the rollout of its weight-loss drugs. The company sells Mounjaro, a weight-loss drug manufactured by Eli Lilly, in South Africa and plans to introduce its own generic version, targeting local markets as well as South America and the Middle East. With demand from Africa currently representing only a small fraction of the global weight-loss drug market projected to reach $100 billion by 2030, obesity cases are on the rise, projected to double by 2050, and causing significant public health concerns. South Africa is emerging as the primary battleground in the continent between leading providers of weight-loss drugs, with Eli Lilly's Mounjaro competing against Ozempic, manufactured by Danish company Novo Nordisk.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}